Click for next page ( 239


The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 238
Appendix F Workshop Agenda and Participants Institute of Medicine Committee to Study Medication Development and Research at the National Institute on Drug Abuse Workshop on Policies to Stimulate Private Sector Development of Anti-Addiction Medications June 13, 1994 Lecture Room, National Academy of Sciences 2101 Constitution Avenue, N.W. Washington, D.C. WORKSHOP AGENDA 8:00~:30 a.m. BREAKFAST 8:30 8:45 OPENING REMARKS Laurence E. Earley, Chairman 8:4~10:45 Panel I: Private Sector Obstacles and Opportunities Moderator: J. Richard Crout Panel: Dee Gillespie, Steve Grossman, Richard Merrill, Sherri Samotin* 10:4~12:30 Panel II: Regulatory Issues Moderator: Herbert Kleber Panel: Robert Angarola, John Coleman, George DeVaux*, Nicholas Reuter, Frank Vocci 238

OCR for page 238
APPENDIX F 12:30-1 :15 LUNCH 1:15-2:30 Panel III: Research and Training Issues Moderator: Kathleen Foley Panel: John Ambre, Ann Geller, Charles Grudzinskas, David Lewis* 2:30-4:00 Panel IV: Treatment Financing Issues Moderator: Peter Carpenter Panel: John Caulkins*, Jack Durell*, Eric Goplerud 4:0~5:00 Plenary Session 5:00 * Presenters 239 Adjourn

OCR for page 238
240 DEVELOPMENT OF MEDICATIONS PARTICIPANT LIST John Ambre American Medical Association Robert Angarola Hyman, Phelps and McNamara Gary Bennett National Institute of Dental Research Ann Carter Drug Enforcement Administration John Caulkins RAND John Coleman Drug Enforcement Administration Leonard Cook National Institute on Drug Abuse James Cooper National Institute on Drug Abuse Paul Coulis National Institute on Drug Abuse Miriam Davis Health Policy Consultant George DeVaux BioDevelopment Corporation Chris Doherty Fox, Bennett and Turner Jack Durell Treatment Research Institute Joel Egertson National Institute on Drug Abuse John Engel Fox, Bennett and Turner Susan Everingham RAND Lorraine Fishback Department of Health and Human Services Gretchen Freshneur Drug Enforcement Administration Jim Friedman Substance Abuse and Mental Health Services Administration Ann Geller American Society of Addiction Medicine Dee Gillespie DuPont-Merck Steve Grossman Hill and Knowlton Charles Grudzinskas National Institute on Drug Abuse Anthony Guarino University of South Alabama

OCR for page 238
APPENDIX F Thomas Hefffier Parke-Davis Pharmaceutical Research James Isbister Pharmavene, Inc. Jerome Jaffe Substance Abuse and Mental Health Services Administration Betty Jones Food and Drug Administration Thomas Kuchenberg Food and Drug Administration Irwin Lerner Hoffman-LaRoche David Lewis Brown University Barbara McGarey National Institutes of Health Richard Merrill University of Virginia School of Law Jacques Normand National Research Council Marcy Oppenheimer Department of Health and Human Services 241 Richard Rettig Institute of Medicine Nicholas Reuter Food and Drug Administration Barbara Roberts Office of National Drug Control Policy Sherri Samotin Wilkerson Group, Inc. Frank Sapienza Drug Enforcement Administration Robert Talbot-Stern Legal Consultant John Thomas BioDevelopment Corporation Frank Vocci National Institute on Drug Abuse Bonnie Wilford George Washington University Curtis Wright Food and Drug Administration Thomas Wyatt National Association of State Controlled Substance Authorities